Prostate Cancer | Specialty

How Sarcoma Experts Work With Community Oncologists

November 14th 2017

Histopathological Diagnosis in Soft Tissue Sarcoma

November 14th 2017

Heterogeneity of Soft Tissue Sarcomas

November 14th 2017

Comparing Abiraterone and Docetaxel in Prostate Cancer Treatment

November 11th 2017

Christopher Sweeney, MBBS, physician, Dana-Farber Cancer Institute, compares treatment with abiraterone verus docetaxel in patients with prostate cancer.

Dr. Hope on the Future of Imaging for Biochemical Recurrent Prostate Cancer

November 10th 2017

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco (UCSF), discusses the future of imaging for biochemical recurrent prostate cancer.

Acquired Mutations Alter Epigenetic Identity in Prostate Cancer

November 8th 2017

Mathieu Lupien, MD, discusses this analysis of the influence of mutations on the epigenetics of prostate cancer.

Drake Highlights PARP Inhibitors, Immunotherapy in Prostate Cancer

November 8th 2017

Charles Drake, MD, PhD, discusses the current status of both PARP inhibitors and immunotherapy in prostate cancer, emphasizing that immunotherapy is still very much a player in the prostate cancer field, with ongoing trials exploring checkpoint inhibitors.

Expert Sheds Light on Prostate Cancer Screening Trial

November 8th 2017

E. David Crawford, MD, discusses the controversy surrounding the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, as well as the role of prostate-specific antigen testing for men with prostate cancer.

Dr. Armstrong Discusses Hereditary Prostate Cancer

November 1st 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses the treatment of hereditary prostate cancer.

Dr. Ryan on Bone-Targeting Agents for Patients With Prostate Cancer

November 1st 2017

Charles J. Ryan, MD, professor of medicine and urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses bone-targeting agents for patients with prostate cancer.

Dr. Berry on LHRH Antagonists Versus Agonists for Prostate Cancer

November 1st 2017

William R. Berry, MD, medical oncologist, Duke University, discusses determining when to use luteinizing hormone-releasing hormone (LHRH) antagonists versus agonists for patients with prostate cancer.

Dr. Cooperberg on Ongoing Trials in Early Prostate Cancer

October 31st 2017

Matthew R. Cooperberg, MD, MPH, an associate professor of urology, epidemiology, and biostatistics, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (USCF), discusses ongoing trials in early prostate cancer.

Dr. Armstrong Discusses AR-V7 Testing in Prostate Cancer

October 24th 2017

Andrew J. Armstrong, MD, associate professor of medicine and surgery, Department of Medicine, Duke University School of Medicine, discusses AR-V7 testing in prostate cancer.

Dr. Zhang Discusses the Impact of the STAMPEDE Trial in Prostate Cancer

October 20th 2017

Tian Zhang, MD, assistant professor of medicine, Duke University School of Medicine, Duke Cancer Institute, discusses the impact of the STAMPEDE trial in prostate cancer.

Dr. Berry on the Differences Between LHRH Antagonists and Agonists

October 19th 2017

William R. Berry, MD, medical oncologist, Duke University, talks about the differences between luteinizing hormone-releasing hormone (LHRH) antagonists and agonists.

Expert Discusses Improving MRI Testing for Prostate Cancer

October 18th 2017

Andrew Vickers, PhD, attending research methodologist at Memorial Sloan Kettering Cancer Center, discusses improving MRI testing for patients with prostate cancer.

Dr. Hope on the Detection Sensitivity of PSMA-PET Scanning

October 17th 2017

Thomas Hope, MD, assistant professor of abdominal imaging and nuclear medicine at University of California, San Francisco, discusses the detection sensitivity of PSMA-PET scanning.

Abiraterone Approaches EU Approval for Newly Diagnosed Hormone-Sensitive Prostate Cancer

October 16th 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanding the existing marketing authorization for abiraterone acetate (Zytiga) in men with newly diagnosed, high-risk metastatic hormone-sensitive prostate cancer.

Advanced Prostate Cancer: Closing Thoughts

October 12th 2017

Promising Agents for the Treatment of Prostate Cancer

October 12th 2017